BlinkLab (ASX:BB1) has initiated a clinical study in partnership with US based Turning Pointe Autism Foundation.
The data obtained during the course of this collaboration will be used to finalise the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.
BlinkLab is an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism.
Read the ASX announcement: https://yourir.info/resources/3449d9aa01a61c6b/announcements/bb1.asx/6A1205872/BB1_BlinkLab_Partnership_with_Turning_Pointe_Autism_Foundation.pdf #BB1